Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Johnson & Johnson Submits An FDA Application For Fixed Combination Of Amivantamab And Recombinant Human Hyaluronidase For Subcutaneous Administration For All Currently Approved Or Submitted Indications Of IV Rybrevant In Certain Type Of NSCLC

Author: Benzinga Newsdesk | June 17, 2024 08:04am

Posted In: JNJ